Sociedad Americana de Hirudoterapia

Antithrombotic drugs in cardiovascular medicine: a year in review

Review published in Current opinion in cardiology (2018)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosIbrahim H et al. · Current opinion in cardiology, 2018

Abstract

PURPOSE OF REVIEW: To provide an up to date review of the most recent randomized clinical trials in the field of antithrombotic drugs for cardiovascular diseases. RECENT FINDINGS: In 2017, low-dose anti-Xa treatment added to aspirin proved to be more efficacious than either treatment alone in patients with stable atherosclerotic disease despite the increase in nonfatal bleeding events. Furthermore, anticoagulation strategy during coronary interventions was again tested in a registry-based trial and showed comparable efficacy and safety between heparin alone and bivalirudin. Data from safety trials demonstrated lower risk of bleeding with dual antithrombotic therapy compared with triple antithrombotic therapy following coronary intervention, albeit these trials were underpowered for efficacy. Although still in its infancy, the role of antithrombotic treatment following transcatheter aortic valve replacement (TAVR) has been investigated in small trials with evidence that a single antiplatelet drug may be noninferior to dual antiplatelet therapy with a better safety profile. SUMMARY: In this review, we discuss the most recent clinical trials investigating antithrombotic drugs for cardiovascular diseases published in 2017.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAspirinCardiovascular DiseasesDrug Therapy, CombinationFactor Xa InhibitorsFibrinolytic AgentsHumansPercutaneous Coronary InterventionRandomized Controlled Trials as TopicTranscatheter Aortic Valve Replacement

Resumen

To provide an up to date review of the most recent randomized clinical trials in the field of antithrombotic drugs for cardiovascular diseases.

Por qué esto importa para la hirudoterapia

This review summarizes 2017 randomized clinical trials of antithrombotic drugs in cardiovascular medicine, covering low-dose anti-Xa therapy added to aspirin, anticoagulation strategies during coronary interventions comparing heparin and bivalirudin, dual versus triple antithrombotic regimens after coronary intervention, and antithrombotic approaches following transcatheter aortic valve replacement. The abstract notes that bivalirudin showed comparable efficacy and safety to heparin alone in a registry-based trial during coronary interventions. The abstract does not mention hirudin, leeches, leech therapy, or the leech secretome, and names bivalirudin without characterizing its pharmacology or derivation. There is no defensible connection to hirudotherapy based on the abstract text.

Citación

Antithrombotic drugs in cardiovascular medicine: a year in review

Ibrahim H et al. · Current opinion in cardiology, 2018

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.